Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-angiogenic Targeted Drugs + Ginsenoside Rg3 + TACE in Unresectable HCC
NCT04523467Unknown
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ginsenoside Rg3 in hepatocellular carcinoma (HCC) (2 arms), sponsored by Eastern Hepatobiliary Surgery Hospital. Primary endpoint: Progression-free survival at 2 years. Status: unknown.
02
Drugs
ginsenoside Rg3
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04523467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04523467.